Adjuvant immune checkpoint inhibitors for urothelial carcinoma: systematic review and Meta-analysis.
Rashid K SayyidRui BernardinoJulian ChavarriagaRavi KumarHarkanwal RandhawaMarian S WettsteinJessica Grace CockburnZachary KlaassenNeil E FleshnerPublished in: World journal of urology (2024)
Adjuvant ICIs confer a DFS benefit following radical surgery for MIUC, particularly among node-positive patients and those who received prior neoadjuvant chemotherapy. The lack of benefit for upper tract disease suggests that alternate adjuvant approaches, including chemotherapy, should be considered for these patients. Tumor PD-L1 status is not a predictive biomarker, highlighting the need for biomarkers in this setting.
Keyphrases
- neoadjuvant chemotherapy
- end stage renal disease
- ejection fraction
- early stage
- newly diagnosed
- chronic kidney disease
- prognostic factors
- lymph node
- peritoneal dialysis
- locally advanced
- minimally invasive
- coronary artery disease
- patient reported outcomes
- acute coronary syndrome
- radiation therapy
- atrial fibrillation
- patient reported
- surgical site infection